Navigation Links
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
Date:7/30/2009

ble levels of virus at weeks 4 and 12 and to achieve SVR; (iii) Anadys' expectation that it will receive 28-day data from the 200 mg dose level by year end and additional data during the first two quarters of 2010; (iv) the antiviral and tolerability profile of ANA598 seen to date, which may not be duplicated in the Phase II study; (v) preclinical properties indicative of likely synergy when used clinically in combination regimens; and (vi) the belief that certain features of the Phase II protocol have the ability to further enhance the competitive position of ANA598. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will have favorable results in the planned Phase II trial. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its product candidates, regulatory developments involving its product candidates and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Current Report on Form 8-K filed on June 4, 2009. All fo
'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
2. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
4. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
5. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... FL (PRWEB) May 26, 2015 Where ... speaker Jack Uldrich says, "The honest answer is that ... deliver four keynote speeches throughout the month of June, ... keynote topics vary from future-proofing to top tech trends. ... Uldrich's research is where the universe is expanding to. ...
(Date:5/25/2015)... May 25, 2015 Phenome Networks, ... provider, announced the availability, beginning May 31st, of its ... of Phenome One solidifies Phenome Networks’ lead in the ... a simple and intuitive breeding workflow based on years ... to customize field design, and more. The new version ...
(Date:5/22/2015)... 2015 According to a new ... 2D Gel Electrophoresis, Agarose & Polyacrylamide Gel, Capillary Electrophoresis, ... Application & by End User - Global Forecast to ... to reach around $1.98 Billion by 2020 with a ... 2020. Browse 226 ma rket ...
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
Breaking Biology Technology:Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 2Futurist Jack Uldrich Says Embracing Our Ignorance is the Key to Unlearning 3Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 2Phenome Networks Announces its Next Generation Plant Breeding Management and Analytics Software 3Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2
... S and CHT , ... Henry Lai, PhD, and Samuel G Franklin, PhD, Bio-Rad Laboratories, Inc., , ... , Introduction , ... been purified , using the conventional process composed of ...
... Kevin McKernan, Jim Yang, Betty Woolf, Rey Sequerra, Kathy Makowski, Tom , ... Beverly, MA 01915, USA, Abstract , ... , and disease susceptibility is becoming, ... Since the completion of the Human, ...
... Agencourts RNAClean kit provides a simple, flexible and highly reproducible ... in common enzymatic , RT and IVT reactions ... gene expression analysis experiments and is easily performed in ... need for vacuum filtration or , centrifugation, and ...
Cached Biology Technology:Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 3Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 4SeeSNP Propietary Analysis Advantages 2SeeSNP Propietary Analysis Advantages 3SeeSNP Propietary Analysis Advantages 4SeeSNP Propietary Analysis Advantages 5SeeSNP Propietary Analysis Advantages 6RNAClean - RNA & cDNA in vitro Reaction Purification 2
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... 11, 2015  Synaptics Incorporated (NASDAQ: SYNA ... today announced the appointment of Wajid Ali ... Officer, reporting to Rick Bergman , President ... Financial Officer, Kathleen Bayless , who announced ... Mr. Ali brings extensive financial management expertise to ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... Blacksburg, Va. -- A special issue of BMC ... scientists developing a universal language to describe the genes ... hosts that they colonize. Eight papers from members of ... efforts to expand The Gene Ontology to include a ...
... a child catching the itchy red rash, chicken pox. The ... was responsible for nearly 4 million cases each year, according ... introduced in 1995 reduced that number by 83 percent. Yet, ... the varicella zoster virus may still be present in your ...
... trying to coax human stem cells to turn into ... used to replace damaged tissue in people with heart ... assistant professor of chemical and molecular engineering in the ... two-year grant from the March of Dimes Foundation to ...
Cached Biology News:Special issue of BMC Microbiology spotlights standardized language for describing microbes 2Special issue of BMC Microbiology spotlights standardized language for describing microbes 3Childhood chicken pox could affect oral health years later 2Researcher seeks to turn stem cells into blood vessels 2Researcher seeks to turn stem cells into blood vessels 3
In plasmid or lambda vector. Please inquire for more details!...
Goat polyclonal to Sarcosine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Full length protein: Sarcosine Oxidase (microbial). Entrez Gene ID: 51268 Swiss Protein ID: ...
... to SARA ( Abpromise for all ... Synthetic peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, ... fly (Drosophila melanogaster) SARA. Conserved sequence ... Gene ID: 9372 ...
Reacts with methylated DNA from plants and vertebrates...
Biology Products: